PROMIS NEUROSCIENCES ($PMN) posted quarterly earnings results on Monday, March 31st. The company reported earnings of -$0.02 per share, beating estimates of -$0.14 by $0.12. The company also reported revenue of $0, equaling estimates of $0 by $0.
You can see Quiver Quantitative's $PMN stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
PROMIS NEUROSCIENCES Insider Trading Activity
PROMIS NEUROSCIENCES insiders have traded $PMN stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $PMN stock by insiders over the last 6 months:
- NEIL CASHMAN (Chief Scientific Officer) purchased 15,000 shares for an estimated $14,595
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
PROMIS NEUROSCIENCES Hedge Fund Activity
We have seen 2 institutional investors add shares of PROMIS NEUROSCIENCES stock to their portfolio, and 9 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ALTIUM CAPITAL MANAGEMENT LP added 581,395 shares (+inf%) to their portfolio in Q3 2024, for an estimated $726,743
- HEIGHTS CAPITAL MANAGEMENT, INC removed 226,687 shares (-58.6%) from their portfolio in Q4 2024, for an estimated $214,853
- ARMISTICE CAPITAL, LLC removed 160,023 shares (-6.0%) from their portfolio in Q4 2024, for an estimated $151,669
- GREAT POINT PARTNERS LLC removed 145,570 shares (-5.2%) from their portfolio in Q4 2024, for an estimated $137,971
- AFFINITY ASSET ADVISORS, LLC removed 30,643 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $29,043
- FIDUCIARY TRUST CO removed 6,425 shares (-32.1%) from their portfolio in Q4 2024, for an estimated $6,089
- ROYAL BANK OF CANADA added 4,741 shares (+635.5%) to their portfolio in Q4 2024, for an estimated $4,493
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
